| Dr James R Campbell Jr, DDS | |
|
202 S 4th St W, Baker, MT 59313 | |
| (406) 778-5150 | |
| (406) 778-5151 |
| Full Name | Dr James R Campbell Jr |
|---|---|
| Gender | Male |
| Speciality | Dentist - General Practice |
| Location | 202 S 4th St W, Baker, Montana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336293547 | NPI | - | NPPES |
| 111197 | Medicaid | MT | |
| 5511536 | Other | MT | BLUECHIP |
| 41167 | Medicaid | ND | |
| 5511531 | Other | MT | BLUECHIP |
| 942710 | Other | ND | BLUE CROSS BLUE SHIELD ND |
| 0111214 | Medicaid | MT | |
| 19064 | Other | MT | BLUE CROSS BLUE SHIELD MT |
| 40784 | Other | MT | BLUE CROSS BLUE SHIELD MT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1223G0001X | Dentist - General Practice | 1906 (Montana) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr James R Campbell Jr, DDS Po Box 1156, Baker, MT 59313 Ph: (406) 778-5150 | Dr James R Campbell Jr, DDS 202 S 4th St W, Baker, MT 59313 Ph: (406) 778-5150 |
News Archive
Saeed A. Jortani, Ph.D., associate clinical professor in the University of Louisville's Department of Pathology and Laboratory Medicine, headed up one of three labs in the United States involved in determining two new markers for acute kidney injury (AKI). The research group's paper, "Validation of Cell-Cycle Arrest Biomarkers for Acute Kidney Injury Using Clinical Adjudication," was posted online Feb. 25 by the American Journal of Respiratory and Critical Care Medicine.
Scientists have hypothesized that the number of immune cells and the amount of cytokines produced in response to SARS-CoV-2 infection in pregnant women change in accordance with the timing of maternal infection in pregnancy. This study is available on the bioRxiv* preprint server.
Everyone knows that tobacco products are bad for your health, and even the new e-cigarettes may have harmful toxins.
Laboratory studies by chemical engineers at UC Santa Barbara may lead to new experimental methods for early detection and diagnosis - and to possible treatments - for pathological tissues that are precursors to multiple sclerosis and similar diseases.
ViroStatics, a US/Italian biopharmaceutical company developing innovative immunotherapies for HIV/AIDS and other chronic diseases, is releasing Phase II data from a randomized, dose-ranging trial of VS411, the Company's novel combination product for treating HIV/AIDS, during the XVII International AIDS Conference this week in Vienna, Austria.
› Verified 1 days ago